We thank BioNTech for recognizing our biostatistics support in the development of a vaccine against COVID-19! We were very happy to add our expertise to this meaningful project and thank the whole team!
Link:
Press release as pdf:
BioNTech Recognizes Employees and Partners for Their Support in Developing Historic Vaccine
Our course “Introduction to R course” will be a 2-day course from 28 to 29 January 2021!
The course, which takes place online, is about providing a solid foundation in R, the popular open source programming language in statistics and data sciences. As a preferred tool for complex data analyses it is applied in every industry. This R programming course will give an introduction to the basics of R. In the two-day course you will learn how to program in R, how to perform data analysis in R and how to visualize your results graphically.
The course is mainly addressed (but not restricted) to professionals who are interested in data science (e.g. Statisticians, SAS Programmers, Data Managers) and who want to learn the very basics of R. Further, this introduction is helpful for participants who wish to brush up on their knowledge in R.
The course will be held in English and the detailed agenda will be sent out a few days before the start of the course. You find more details here!
Our Christmas Party was a special one this year. Due to the current situation the event was taking place virtually. Together in groups we prepared and enjoyed delivered food packages. On the menu was a classic Christmas duck dish or a tasty vegan option followed by an orange cake with roasted apple and cinnamon mousse.
The second highlight of the evening was an online escape room game. Some of the teams completed the challenge within the time limit of one hour. The others are still searching for the person how stole the Christmas wish lists – we hope that they are successful, so that all your Christmas wishes will come true. With this in mind, we wish you relaxing Christmas holidays as well as health and happiness for the new year!
A new study in collaboration with Universitätsklinikum Hamburg-Eppendorf (UKE) and CTC North GmbH & Co. KG has been approved by the German Gemeinsamer Bundesausschuss (G-BA) on December 4. The G-BA has commissioned the UKE to research the benefits of allogeneic stem cell transplantation to treat multiple myeloma in relapsed/progressive patients. The project is led by principal investigator Prof. Dr. Nicolaus Kröger of UKE. Staburo GmbH is responsible for the statistical analysis. More information can be found in the press release of the G-BA (https://www.g-ba.de/presse/pressemitteilungen/917/).
On November 27, Staburo Managing Director Dr. Hannes Buchner gave a talk at the 74th workshop of the APF (Arbeitsgruppe Pharmazeutische Forschung) of the Deutsche Region der Internationalen Biometrischen Gesellschaft (IBS-DR). Together with Kaspar Rufibach from Roche Pharma, he presented new findings from their Oncology Estimand Working Group in the talk “Estimands update: Summary of world-wide authority interaction”. In his part of the talk, Dr. Hannes Buchner explained how to correct for treatment switching in clinical trials and how it can be included into the estimand framework.
The virtual APF workshop titled “COVID-19: Effects on statistics, methodological aspects and operational implications” was organised for biometricians working in pharmaceutical research and development, to accelerate the exchange of methods among colleagues as well as to transport mutual information on official regulations, methodological developments, and scientific events.
UPDATE 22-DEC-2020 (Thanks for sharing, Kaspar Rufibach)
For those interested to learn more: the slidedeck Hannes Buchner and Kaspar Rufibach presented is available on the webpage of the oncology estimand WG: www.oncoestimand.org (go to “Events”).
Staburo participated in the 2020 Global Clinical Trial Disclosure & Data Transparency Conference hosted by the Drug Information Association (DIA) from the 16 – 18 November, this year online due to – you guessed it – covid19.
During the conference different regulatory agencies such as the FDA and the EMA provided updates concerning their disclosure platforms. The FDA provided an overview of new and upcoming features of ClinicalTrials.gov which are of immediate use to us in our day to day work disclosing studies on this platform. The EMA discussed the upcoming release of their new central European disclosure platform CTIS (Clinical Trials Information System) which will mark a major shift in the way clinical trials are disclosed in the EU.
Besides the regulatory agencies a range of industry experts joined the conference, leading to interesting discussions about topics such as the global harmonization, BREXIT, disclosing medical device studies and the future of clinical trial regulation. These talks provided valuable insights into the current state and future goals of global clinical trial disclosure.
We are looking forward to participating in next year’s conference where we can hopefully meet the speakers and attendees in real life!
If you have any questions about our disclosure services, don’t hesitate to contact us!
Recent Comments